• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by FibroBiologics Inc.

    4/23/25 6:05:38 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FBLG alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No.__)

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐ Definitive Proxy Statement
    ☒ Definitive Additional Materials
    ☐ Soliciting Material under § 240.14a-12

     

    FIBROBIOLOGICS, INC.
    (Name of Registrant as Specified In Its Charter)
     
     
    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply)

     

    ☒ No fee required.
    ☐ Fee paid previously with preliminary materials.
    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

     
     

     

     

     

     

    Get the next $FBLG alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FBLG

    DatePrice TargetRatingAnalyst
    12/12/2024$12.00Buy
    Rodman & Renshaw
    10/30/2024$12.00Buy
    H.C. Wainwright
    9/24/2024$12.00Buy
    Maxim Group
    More analyst ratings

    $FBLG
    SEC Filings

    See more
    • FibroBiologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      7/3/25 4:03:02 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      6/16/25 5:00:28 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - FibroBiologics, Inc. (0001958777) (Filer)

      6/13/25 4:00:26 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Scientific Officer Khoja Hamid bought $16,800 worth of shares (20,000 units at $0.84), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      5/27/25 5:56:53 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer O'Heeron Pete bought $16,269 worth of shares (8,500 units at $1.91), increasing direct ownership by 0.14% to 6,056,647 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:49 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Khoja Hamid bought $19,000 worth of shares (10,000 units at $1.90), increasing direct ownership by 800% to 11,250 units (SEC Form 4)

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      8/12/24 9:58:39 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

      Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      12/12/24 8:54:24 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on FibroBiologics with a new price target

      H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      10/30/24 6:37:36 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on FibroBiologics with a new price target

      Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

      9/24/24 7:59:12 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Niklas Victoria Ninon Olivia

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:30:37 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Link Matthew

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:26:50 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoffman Robert E.

      4 - FibroBiologics, Inc. (0001958777) (Issuer)

      6/12/25 7:23:52 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

      HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced it has closed the third $5 million tranche of the previously announced Standby Equity Purchase Agreement (the "SEPA") with YA II PN, Ltd. ("Yorkville"), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over th

      6/16/25 4:35:00 PM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics to Present at the BIO International Convention 2025

      HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, will present a company update at the BIO International Convention 2025, June 16-19, 2025, in Boston, MA. The presentation will include recent corporate milestones and research advances using fibroblast-based technology for indications such as wound healing, multiple sclerosis, and psoriasis. "The BIO Interna

      6/16/25 9:50:45 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

      6/9/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FBLG
    Leadership Updates

    Live Leadership Updates

    See more
    • FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

      6/9/25 8:30:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Set to Join Russell 2000® Index

      HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b

      6/13/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FibroBiologics Appoints Ruben A. Garcia as General Counsel

      HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team.   "The addition of Ruben as our General Counsel rep

      3/6/24 9:31:00 AM ET
      $FBLG
      Biotechnology: Pharmaceutical Preparations
      Health Care